Manipal Hospitals Q1 FY27 Revenue at ₹3,091 Cr, up 38.1%; EBITDA ₹749 Cr
Manipal Hospitals reported Q1 FY27 revenue of ₹3,091 crore, a 38.1% YoY increase. EBITDA grew 26.4% to ₹749 crore. Inpatient volumes rose 38.8% and outpatient volumes increased 26.0%. Occupancy improved to 65.0%. The company noted strong performance post-listing and progress in Sahyadri integration.
The announcement details robust financial and operational performance for the quarter, including significant revenue growth and improved key metrics. This is the company's first results announcement post-listing, making it highly material for investors.
The company reported strong year-on-year growth in revenue and EBITDA, along with significant increases in patient volumes and occupancy. The positive commentary from the CEO further reinforces the positive sentiment.
Manipal Health Enterprises Limited (Manipal Hospitals) announced its financial results for the quarter ended June 30, 2026 (Q1 FY27), reporting a revenue of ₹3,091 crore, a 38.1% year-on-year increase. EBITDA stood at ₹749 crore, reflecting a 26.4% year-on-year growth. Excluding a one-off gain of ₹15 crore in Q1 FY26, EBITDA growth was 29.7%.
Patient volumes saw significant growth, with inpatient volumes up 38.8% and outpatient volumes up 26.0%. Occupancy improved by 290 basis points to 65.0%. Average Revenue Per Occupied Bed (ARPOB), excluding the Sahyadri acquisition's impact, increased by 8.7% year-on-year to ₹77,200 per day.
The integration of Sahyadri Hospitals contributed to the network's performance, with its revenue growing 12.8% and EBITDA growing 18.7% year-on-year. High-acuity specialties, particularly Oncology and Orthopedics, drove momentum, with inpatient revenue growth of 62% and 49%, respectively.
Dilip Jose, Managing Director & CEO, highlighted the company's strong performance as a listed entity, emphasizing sustained patient demand, growth in high-acuity specialties, and the ongoing integration of Sahyadri. He noted the IPO provides flexibility for investments in capacity, technology, and clinical excellence.
What to do with a filing like this
Manipal Health Enterprises Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Manipal Health Enterprises Limited. Read the original for the full detail.